Evidence map›Paper›PMID 41852923›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2026

Chromatin regulators

Zhipeng Wang, Jie Wang, Shuang Chen, Ruicheng Wu, Zhouting Tuo, Luxia Ye, Koo Han Yoo, Dengxiong Li, Xiaodong Jin, Wei Xiong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhipeng Wang *Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Jie Wang *Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
Shuang Chen *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Ruicheng WuDivision of Surgery & Interventional Science, University College London, London W1W 7TS, UK.
Zhouting TuoDepartment of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Luxia YeDepartment of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000, China.
Koo Han YooDepartment of Urology, Kyung Hee University, Seoul 17104, South Korea.
Dengxiong LiDepartment of Urology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310053, China.
Xiaodong JinDepartment of Urology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310053, China.
Wei XiongDepartment of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China.
Dechao FengDivision of Surgery & Interventional Science, University College London, London W1W 7TS, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To identify chromatin regulators (CRs)-based molecular subtypes and risk scores for accurately predicting biochemical recurrence (BCR) after radical prostatectomy (RAP) in prostate cancer (PCa) patients. Methods: Differentially expressed genes (DEGs) between tumor and normal samples from The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO) databases were intersected with CR-related and prognostic genes. Consensus clustering, risk score analysis, functional analysis, immune microenvironment, m6A, and heterogeneity assessments were performed using R software. Results: Conclusions:

Indexed as

biochemical recurrencechromatin regulatormolecular subtypesPI3K/AKT pathwayProstate cancer

Identifiers

PMID41852923
PMCPMC12993476

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.